MONMOUTH JUNCTION, N.J.,
Feb. 24, 2021 /PRNewswire/
-- CytoSorbents Corporation (NASDAQ: CTSO), a critical
care immunotherapy leader commercializing its CytoSorb® blood
purification technology to treat deadly inflammation in
critically-ill and cardiac surgery patients around the world,
announces its participation the Cowen 41st Annual Health
Care Conference. Chief Executive Officer, Dr. Phillip Chan, MD, PhD will present a brief
overview of the Company's progress and outlook followed by a
fireside chat with Joshua Jennings,
MD, Managing Director, Senior Research Analyst, Equity Research at
Cowen and Company. Company management will also meet with investors
in 1x1 meetings throughout the day. To schedule a meeting
with management, please contact your Cowen representative.
CytoSorbents CEO Dr. Phillip Chan to
discuss company's progress with Cowen's Josh Jennings, MD, Senior Research Analyst
Cowen Annual Health Care Conference
When: Wednesday, March 3, 2021
from 12:20PM-12:50PM EST
Webcast: Cowen Presentation Webcast Link
About CytoSorbents Corporation
(NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care
immunotherapy, specializing in blood purification. Its flagship
product, CytoSorb® is approved in the European Union with
distribution in 67 countries around the world, as an extracorporeal
cytokine adsorber designed to reduce the "cytokine storm" or
"cytokine release syndrome" that could otherwise cause massive
inflammation, organ failure and death in common critical illnesses.
These are conditions where the risk of death is extremely high, yet
no effective treatments exist. CytoSorb® is also being used during
and after cardiac surgery to remove inflammatory mediators that can
lead to post-operative complications, including multiple organ
failure. CytoSorb® has been used in more than 121,000 human
treatments to date. CytoSorb has received CE-Mark label
expansions for the removal of bilirubin (liver disease), myoglobin
(trauma) and both ticagrelor and rivaroxaban during cardiothoracic
surgery. CytoSorb has also received FDA Emergency Use
Authorization in the United States
for use in critically-ill COVID-19 patients with imminent or
confirmed respiratory failure, in defined circumstances.
CytoSorb has also been granted FDA Breakthrough Designation for the
removal of ticagrelor in a cardiopulmonary bypass circuit during
emergent and urgent cardiothoracic surgery.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received non-dilutive
grant, contract, and other funding of more than $38 million from DARPA, the U.S. Army, the U.S.
Department of Health and Human Services, the National Institutes of
Health (NIH), National Heart, Lung, and Blood Institute (NHLBI),
the U.S. Army, the U.S. Air Force, U.S. Special Operations Command
(SOCOM), Air Force Material Command (USAF/AFMC), and others. The
Company has numerous products under development based upon this
unique blood purification technology protected by many issued U.S.
and international patents and multiple applications pending,
including ECOS-300CY™, CytoSorb-XL™, HemoDefend-RGC™,
HemoDefend-BGA™, VetResQ™, K+ontrol™, ContrastSorb,
DrugSorb, and others. For more information,
please visit the Company's websites at www.cytosorbents.com and
www.cytosorb.com or follow us on Facebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions, including statements regarding our expectations
about our cash runway, the advancement of our trials, our plans to
initiate new trials, our goals to develop and commercialize
CytoSorb and the timing thereof, the potential impact of COVID-19
on our operations and milestones, and are not historical
facts and typically are identified by use of terms such as "may,"
"should," "could," "expect," "plan," "anticipate," "believe,"
"estimate," "predict," "potential," "continue" and similar words,
although some forward-looking statements are expressed differently.
You should be aware that the forward-looking statements in this
press release represent management's current judgment and
expectations, but our actual results, events and performance could
differ materially from those in the forward-looking statements.
Factors which could cause or contribute to such differences
include, but are not limited to, risks discussed in our Annual
Report on Form 10-K, filed with the SEC on March 5, 2020, as updated by the risks reported
in our Quarterly Reports on Form 10-Q, and Current Reports on Form
8-K, and in the press releases and other communications to
shareholders issued by us from time to time which attempt to advise
interested parties of the risks and factors which may affect our
business. We caution you not to place undue reliance upon any such
forward-looking statements, particularly in light of the current
coronavirus pandemic, where businesses can be impacted by rapidly
changing state and federal regulations, as well as the health and
availability of their workforce. We undertake no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise, other
than as required under the Federal securities laws.
Please Click to Follow Us on
Facebook and Twitter
Cytosorbents
Contact: Amy Vogel
Investor
Relations
732-398-5394
avogel@cytosorbents.com
|
Public Relations
Contact:
Eric Kim
Rubenstein Public
Relations
212-805-3052
ekim@rubensteinpr.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cytosorbents-to-present-at-the-cowen-41st-annual-health-care-conference-301234386.html
SOURCE CytoSorbents Corporation